US 12,466,892 B2
Systems and methods for targeting cancer cells
Wendell A. Lim, San Francisco, CA (US); Olga G. Troyanskaya, Princeton, NJ (US); Benjamin Vandersluis, New York, NY (US); and Ruth Dannenfelser, Princeton, NJ (US)
Assigned to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US); THE TRUSTEES OF PRINCETON UNIVERSITY, Princeton, NJ (US); and THE SIMONS FOUNDATION, INC., New York, NY (US)
Appl. No. 17/291,794
Filed by The Regents of the University of California, Oakland, CA (US); The Trustees of Princeton University, Princeton, NJ (US); and The Simons Foundation, Inc., New York, NY (US)
PCT Filed Nov. 7, 2019, PCT No. PCT/US2019/060357
§ 371(c)(1), (2) Date May 6, 2021,
PCT Pub. No. WO2020/097395, PCT Pub. Date May 14, 2020.
Claims priority of provisional application 62/757,595, filed on Nov. 8, 2018.
Prior Publication US 2022/0127373 A1, Apr. 28, 2022
Int. Cl. A61K 39/00 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/40 (2006.01)
CPC C07K 16/3015 (2013.01) [A61K 39/00 (2013.01); A61K 39/0011 (2013.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4202 (2025.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 16/28 (2013.01); C07K 16/40 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/47 (2023.05); A61K 2239/49 (2023.05); A61K 2239/54 (2023.05); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01); C07K 2319/00 (2013.01)] 3 Claims
 
1. An in vitro or ex vivo genetically modified cytotoxic immune cell, wherein the cytotoxic immune cell is genetically modified to produce: (a) a binding triggered transcriptional switch (BTTS) that recognizes PTPRZ1, and (b) an antigen-specific therapeutic that recognizes IL13RA2, wherein binding of the BTTS to PTPRZ1 induces expression of the antigen-specific therapeutic by the cell.